原发性胃非何杰金淋巴瘤

本文总结了我院１９８５年－１９８９年收治的２８例原发性胃非何杰金淋巴瘤的临床治疗经验。作者分析了手术治疗ｐｇＮＨＬ的必要性，并强调了联合治疗的意义。     

胃原发非何杰金恶性淋巴瘤70例临床分析

淋巴结外恶性淋巴瘤占全部恶性淋巴瘤的1/4,且以胃肠道恶性淋巴瘤为多见,其中原发胃非何杰金恶性淋巴瘤(PGL)又占首位。文献报道PGL占胃恶性肿瘤的1%～4％,但大组病例报道不多。我院32年外科治疗PGL70例,占同期胃恶性肿瘤的2.75％。本文重点讨论PCL的预后因素。     

原发胃非何杰金恶性淋巴瘤：附83例临床分析

报告天津肿瘤医院３６年来，外科治疗原发非何杰金恶性淋巴瘤（ＰＧＬ）８３例，术前确诊率为３７％。Ｉ期６例，Ⅱ期２７例，Ⅲ期２１例，Ⅳ期２９例。根治性切除的５年生存率９０％，高于胃癌的３３％。总的８３例３、５、１０、１５、２０年的生存率分别为４８％，３８％，２１％，１０％，８％，并重点讨论了影响预后的因素。     

原发性胃恶性淋巴瘤70例报告

１９５８年～１９８９年收治原发性胃恶性淋巴瘤７０例，男３９例、女３１例。５５例随访５年以上。年龄１８岁～６９岁，平均年龄４０．１岁。患者主要临床表现为上腹疼痛及食欲下降，症状无特异性，发病部位以胃窦最多见，有４６例占６５．３％。全组患者５年生存率５６．４％。有淋巴结转移及无淋巴结转移患者的５年生存率分别为３５．０％、７７．８％，二者比较，有非常显著差异。作者认为早期诊断及综合治疗是提高原发性胃恶性淋巴瘤生存率的关键。     

54例原发胃非何杰金淋巴瘤预后因素分析

目的 :分析原发胃非何杰金淋巴瘤 (PG- NHL )经不同方法治疗后的结果及预后因素。材料与方法 :1984年～ 1992年共收治 5 4例 PG- NHL ( 期 19例 , 期 2 3例 , 期 6例 , 期 6例 .4 5例作胃根治术 ,7例作探查术 .术后无辅助治疗 2例 ,4 3例作放疗、化疗或放疗加化疗综合治疗。结果 : ～ 期 5年生存率分别为 94 .7%± 13.5 %、79.1%± 12 %、80 .0 %± 2 5 .3%和 16 .7%± 15 .2 % (生命表法μ检验 )。影响预后的主要因素是病理分期与术后辅助治疗的策略 ,其次是原发肿瘤的体积、单发或多发。结论 :肿瘤侵及粘膜层或浅肌层属于 期早 ,根治术后有 /无辅助治疗 ,其疗效相同。已侵及胃全层的 期晚和 期应作全腹放疗 , 期宜先放疗后化疗 , 期应先化疗后放疗的综合治疗。放疗腹部中平面剂量为 4 0～ 4 5 Gy,化疗常用阿霉素、环磷酰胺、长春新碱、平阳霉素和强的松 (CHOP- BLM)的方案 ,4～ 6周期     

原发性胃淋巴瘤的诊断和治疗新策略

原发性恶性胃淋巴瘤(primary malignant gastric lymphoma,PMGL)是仅次于胃癌的高发胃肿瘤,胃原发性淋巴瘤的病因及发病机制尚不明了.PMGL发病初期常无症状,随着疾病的发展,逐渐出现一些非特异性的消化道症状和体征,与消化道的良性疾病或消化道癌的表现难以区别.PMGL的分类可参照WHO的B细胞及T细胞淋巴瘤的分类标准.由于胃恶性淋巴瘤临床表现缺乏特异性,因此其术前诊断率不高.胃镜检查是术前诊断的主要手段,镜下常表现为胃腔内巨大隆起性黏膜下肿块或表浅的溃疡,与良性淋巴细胞增生和分化差的胃癌较难鉴别.随着影像学技术的发展,国外报道EUS作为评价胃淋巴瘤浸润范围、组织类型及对治疗的反应有重要价值.目前,对于胃原发性淋巴瘤尚无统一和公认的最佳治疗方案,但其总体趋势是向综合治疗发展,尽量进行胃保留的手术治疗,以提高患者生存质量为治疗目的.     

59例原发性胃非霍奇金淋巴瘤的临床分析

背景与目的:胃肠道是非霍奇金淋巴瘤最常侵犯的结外器官,但其标准的治疗方法目前仍未确定,本文拟通过分析有关资料,探讨原发性胃非霍奇金淋巴瘤的临床特征及治疗策略。方法:收集1980年1月至2002年1月在中山大学肿瘤防治中心收治的59例原发性胃非霍奇金淋巴瘤的临床资料,回顾性分析其临床特点和治疗方式对患者生存期的影响。结果:78.0%原发性胃非霍奇金淋巴瘤Lugano分期为Ⅰ～Ⅱ期,按工作分型78.0%病理类型为中度恶性,免疫分型以B细胞为主(占93.9%)。本组患者采用手术联合化疗37例(62.7%),单纯化疗17例(28.8%),单纯手术5例(8.5%)。总的2、5和10年生存率分别76.4%、63.7%和42.5%,其中中度恶性淋巴瘤(包括免疫母细胞淋巴瘤)手术联合化疗者与单纯化疗者5年生存率差异无统计学意义(52.5%vs.57.1%)。结论:中高度恶性原发性胃非霍奇金淋巴瘤在治疗策略上应采用化疗为主治疗模式,手术的作用尚需前瞻性随机研究进一步证实。     

原发性胃恶性淋巴瘤的诊断和治疗

原发性胃恶性淋巴瘤发生率低，术前较难诊断。本文报告１２例，半数病人术前得到明确诊断，经手术和化疗，已有６例生存超过五年。     

Primary Extranodal Non-Hodgkin's Lymphoma in Adults: Clinicopathological and Survival Characteristics

Among 318 cases of non-Hodgkin's lymphoma (NHL) treated in our unit, 145 (45.6%) had primary extranodal NHL (PE-NHL). The stomach was the most common site (42.1 %), followed by the PE-NHL of the head and neck region. Histologically aggressive histologies (65.5% intermediate and 20.7% high grade) predominated. 89.6% of the cases were localized (stage Ie, 51% and stage II, 38.6%) but 28% had B symptoms. CR was achieved in 82.1 % of the cases. 5-years disease free survival and overall survival were both 65%. Factors that influence prognosis were stage and high grade histology. Among various primary sites the Waldeyer's ring, small intestine and testes had the worse prognosis. Compared to nodal NHL, the PE-NHL were more frequently localized, belonged more often to aggressive histologies and had more often distal extranodal relapses. CR rates and disease free and overall survival were significantly better for PE-NHL. The survival rates, however, listed according to stage and histology for nodal and PE-NHL were not different.

We conclude that although PE-NHL differed from nodal NHL in several respects, prognosis is mainly a factor of stage and histology rather than of the primary localization per se.     

Gastrointestinal Non-Hodgkin's Lymphoma

The records of 77 patients with gastrointestinal Non-Hodgkin's Lymphoma (GI-NHL) diagnosed from 1972 to 1988 were reviewed. There were 47 male and 30 female patients, median age 56 years (range 20-82 years). Twenty-four patients had stage I disease at presentation, 25 stage II, 8 stage III and 20 stage IV. The primary site was stomach for 32 patients, small bowel for 30, colon for 10, and 5 patients had multiple areas of involvement. Six patients had low grade histology, 59 intermediate grade and 12 high grade histology. Forty-two stage I and II patients underwent laparotomy; 30 had complete surgical resection, and 42 had chemotherapy. Only 21 stage III and IV patients underwent laparotomy; 15 had bowel resection and 24 had chemotherapy. Forty-one patients had evaluable disease prior to chemotherapy. Fifty-six percent achieved complete remission and 32% partial remission. At a median follow up of 46 months the median survival is 31 months, and predicted 5 and 10 year survivals are 61% and 42% respectively. Survival correlated most strongly with stage of disease at presentation (p = 0.003). Projected 10 year survival for stage I is 84%, stage II 52%, stage III 38% and no stage IV patients are alive at 10 years. Survival was significantly longer for stage I and II patients who underwent complete surgical resection (p = 0.003), but surgery did not alter survival for stage III or IV patients. Sex, the presence of B symptoms, histologic subtype or site of primary GI-NHL did not demonstrate significant correlation with prognosis.     

Gastric amyloidoma in patient after remission of Non-Hodgkin's Lymphoma

Amyloidosis is commonly systemic, occasionally organ-limited, and rarely a solitary localized mass. The latter, commonly referred to as tumoral amyloidosis, is described as occurring in nearly every organ/tissue. Only a few reports of gastric amyloidosis exist today. We describe a 72 year-old black male from Barbados presenting with 3 d of diffuse abdominal pain. His medical history included Non-Hodgkin's Lymphoma diagnosed five years ago, status-post six rounds of cyclophosphamide, adriamycin, vincristine, prednisone chemotherapy, and currently was in remission. On computed tomography scan of the abdomen, thickening and calcification of the gastric wall was noted along with pneumatosis. On esophagogastroduodenoscopy, a large circumferential friable mass was seen from the gastroesophageal junction to the body. A large non-bleeding 3 cm polyp was also seen in post bulbar area of duodenum. Biopsies were stained with Congo red and gave green birefringence under polarized light, consistent with tumoral amyloidosis. Positron emission tomography scan revealed diffuse gastric mucosa uptake compatible with gastric malignancy without metastatic foci. Treatment for gastric amyloidomas has presently been one of observation or, at most, resection of the amyloid mass. It is not known if our patient required the same approach or if this warranted the re-institution of chemotherapy for Non-Hodgkin's Lymphoma. Until more reports of tumoral amyloidosis are made known, treatment as well as prognosis remain uncertain.     

原发结外非霍奇金淋巴瘤110例临床分析

目的:探讨原发结外非霍奇金淋巴瘤(PE-NHL)的发病情况、临床特点、诊断及治疗.方法:回顾性分析苏州大学附属第二医院2001年1月～2008年5月收治的PE-NHL 110例.结果:110例PE-NHL占同期收治恶性淋巴瘤患者的60.11%(110/183);原发部位广泛,常见部位依次为胃肠道21.82%(24/110)、Waldeye环10.91%(12/110)、鼻腔和软组织各9.10%(10/110)、纵隔7.27%(8/110)、其他少见部位41.82%(46/110);首发表现以原发器官肿大或肿块为主(77.27%),无特异性;90例患者国际预后指教(IPI)评分:低、中、高危组分别占41.11%、44.44%、14.44%.93例进行免疫分型:B细胞型69.90%,T细胞型30.10%;95例接受治疗,CR 61.05%,PR 16.84%,总有效率77.89%,中位生存时间30个月(2～86个月),5年总生存率27%.24例原发胃肠道非霍奇金淋巴瘤(PGIL),其临床特征与非原发胃肠道组比较无统计学差异,治疗23例,CR 65.21%,PR 17.39%,总有效率82.60%,中位生存时间24个月(2～78个月),5年总生存率30%.结论:本组资料中PE-NHL比例高达60.11%,超过结内淋巴瘤;其首发部位广泛,临床表现多样但无特异性;全面认识本病、遵循合理的诊治模式是提高疗效的关键.     

Intermediate and High-Grade Gastric Non-Hodgkin's Lymphoma: A Prospective Study of Non-Surgical Treatment with Primary Chemotherapy, with or without Radiotherapy

The role of surgery as initial treatment in gastric lymphoma remains controversial. We have prospectively evaluated a stomach conservation strategy in histologically aggressive gastric lymphoma, using primary adriamycin-containing chemotherapy, followed by involved-field radiotherapy in patients with limited disease. Twenty-six patients (median age 69 years) were entered in this study; 15 had stage I disease, 7 had stage II disease and 4 had stage IV disease. The chemotherapy combinations were CHOP (18 patients) and ProMACE/MOPP (8 patients). Radiotherapy was given to 11 patients. Of the 24 patients evaluated for response, 18 (75%) achieved endoscopically-confirmed complete response and 4 (17%) partial response. During follow-up (median 22 months), none of the complete responders developed recurrent lymphoma. Gastric resection was performed in 1/26 patients who did not respond to primary chemotherapy. There were no cases of perforation, but three patients (12%) developed acute gastro-intestinal bleeding a few days after the onset of chemotherapy, one of whom required a surgical devascularization procedure. There was no treatment-related mortality. These data further support the non-surgical approach in histologically aggressive gastric lymphoma, using primary chemotherapy with or without radiation therapy.     

胃原发性MALT淋巴瘤临床病理分析

目的：探讨我区胃原发性黏膜相关淋巴组织型结外边缘区B细胞淋巴瘤(下称MALT淋巴瘤)的临床病理特点。方法：对14例胃原发性MALT淋巴瘤临床病理资料进行回顾性分析，并用免疫组化S-P法作下列抗体染色：HP、LCA、CD3、CD5、CDIO、CD20、cyclinD1、lgM、κ、λ及BCL-2等。结果：男性5例，女性9例，中位年龄56岁。7例位于胃窦部，7例位于胃体。临床分期为：Ⅰ期8例(57％)．Ⅱ期6例。14例均表现为溃疡型病灶，病灶周围黏膜呈息肉样增生。组织学特点为：肿瘤细胞以边缘区B细胞为主．混有少量母化的细胞及浆细胞，可见淋巴上皮病变及反应性淋巴滤泡，7例(50％)可见向弥漫性大B细胞淋巴瘤转化区。免疫组化染色：HP阳性7例(50％)，肿瘤细胞表达LCA、CD20、IgM；表达单一的轻链κ阳性5例、λ阳性9例；CD3、CD5、CD10、cyclinD1均阴性，中小肿瘤细胞BCL-2阳性，大细胞BCL-2阴性。结论：胃MALT淋巴瘤好发于中老年女性．易向弥漫性大B细胞淋巴瘤转化。     

Primary Pleural Extranodal Non-Hodgkin's Lymphoma Presenting As Pleural Thickening-A Case Report

Primary pleural lymphoma is a rare entity that has been described in association with human immunodeficiency virus (HIV) infection or pyothorax. This paper reports on a 27 year old man with no history of HIV infection or pyothorax who presented with progressive dyspnea and heaviness of chest.Chest radiography revealed complete opacification of the left hemithorax, and contrast enhanced computed tomography showed large left pleural effusion and homogeneous, extensive thickening of the parietal pleura. CT guided biopsy of thickened pleura is suggestive of non-Hodgkin's lymphoma-T cell lymphoblastic variety. Physicians should be aware of this rare location of primary pleural lymphoma manifested by thickening of the pleura.     

Polycythaemia Vera Following Non-Hodgkin's Lymphoma

A patient with non-Hodgkin's lymphoma (NHL) who developed polycythaemia Vera (PV) is reported. Diffuse large-cell NHL was diagnosed and he was subsequently treated with combination chemotherapy including high dose cyclophosphamide and procarbazine. Four and a half years after chemotherapy splenomegaly developed, coincidently with the appearance of high Hb values, RBC and platelet counts. The screening tests for PV were consistent with this diagnosis, while the search for lymphoma activity was negative. To the best of our knowledge, the present case represents the first well-documented instance of PV following NHL.     

Bone Marrow Transplantation in Low-Grade Non-Hodgkin's Lymphoma

The low-grade histologic types constitute one quarter of all non-Hodgkin's lymphomas (NHL). Conventional chemotherapy and chemo-radiation therapy have failed to significantly alter the course of this disease, and most patients eventually succumb to lymphoma. Despite the fact that NHLs exhibit a steep dose-response relation to cytotoxic therapy, fewer than 30% of eligible patients undergo bone marrow transplantation. Reasons for fewer patients receiving this course of treatment include: elderly patient population, extensive previous chemotherapy and/or radiation therapy, high incidence of bone marrow involvement, and transformation to higher grade NHLs. In recent years, improvements in several areas have enhanced the therapeutic index for bone marrow transplantation. These advances include the use of more effective preparative regimens, recombinant hematopoietic growth factors, extended-spectrum antibiotics, and an increased expertise in blood transfusion techniques and practices. Other, more effective strategies include sophisticated in vitro bone marrow purging approaches and peripheral blood progenitor cell collection. As a result, more patients have been able to receive dose-intensive therapy followed by hematopoietic cellular rescue. Although follow up is short in most series, encouraging results have stimulated some centers to begin transplanting responding patients earlier in their disease course; in more than 200 patients treated in this fashion, long-term disease-free survival has been achieved in nearly 70% of patients, some patients for a period of greater than 6 years. The new purine analogues fludarabine, pentostatin, and 2-chlorodeoxyadenosine also have shown promise in both initial and salvage treatment of low-grade NHLs. It remains to be determined whether this group of drugs will be complimentary to the bone marrow and/or peripheral blood progenitor cell transplant approach.     

原发性软组织内非霍奇金淋巴瘤2例并文献复习

目的 探讨原发性软组织内非霍奇金淋巴瘤的临床病理学特征.方法 对2例原发性软组织内非霍奇金淋巴瘤进行临床、病理组织学和免疫组织化学观察,并结合文献探讨其临床表现、病理形态及鉴别诊断.结果 本病临床上无特异性,2例患者平均年龄57岁.证实均为弥漫性非霍奇金淋巴瘤,1例为B细胞性,1例为T细胞性.组织学上见肿瘤细胞弥漫分布,细胞呈圆形或卵圆形,核仁明显,核分裂像易见.免疫表型LCA、CD43、CD3、CD20、CD79α阳性;Vimentin、Actin、Myoglobin、Myosin、EMA、CK、CgA、Syn、NSE、Melon A和S-100 2例瘤细胞均不表达.结论 原发性软组织淋巴结外恶性淋巴瘤比较少见,中老年患者出现软组织内弥漫性肿块,应考虑到原发性恶性淋巴瘤的可能性.本病的明确诊断依赖病理学,而免疫组化染色在鉴别诊断中发挥重要作用.